Hope Therapeutics, a wholly-owned subsidiary of NRx Pharmaceuticals (NRXP), announced engagement of BTIG, a leading global financial services firm specializing in investment banking, institutional trading, research and related brokerage services. The scope of the engagement includes advisory and assistance in evaluating strategic and financing options available to the company and identification, evaluation and negotiation of potential acquisition targets for the Hope network of clinics, as well as equity and debt financing structures.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRXP:
- Psychedelic: atai Life Sciences reports BPL-003 study results
- NRx Pharmaceuticals invests $27M in subsidiary Hope for clinic acquisitions
- NRx Pharmaceuticals announces $3.5M registered direct offering
- NRX Pharmaceuticals Board Changes and Nasdaq Compliance
- NRx Pharmaceuticals regains Nasdaq compliance